Literature DB >> 31101889

Direct adjusted survival and cumulative incidence curves for observational studies.

Zhen-Huan Hu1, Robert Peter Gale2, Mei-Jie Zhang3.   

Abstract

SERIES EDITORS' NOTE: Large randomized clinical trials testing the impact of subject-, disease- and transplant-related co-variates on outcomes amongst recipients of haematopoietic cell transplants are uncommon. For example, who is the best donor, which is the best pretransplant conditioning regimen or the best regimen to prevent or treat acute and/or chronic graft-versus-host disease. To answer these questions we often rely on analyses of data from large observational datasets such as those of the Center for International Blood and Marrow Transplant Research (CIBMTR) and the European Society for Blood and Marrow Transplantation (EBMT). Such analyses have proved extremely important in advancing the field. However, in contrast to randomized trials, we cannot be certain potentially important prognostic or predictive co-variates are balanced between cohorts selected for comparison from an observational dataset, a limitation which can lead to incorrect conclusions. In the typescript which follows the authours describe a method to adjust for known imbalances in co-variates and get a closer approximation of the truth. They give two examples, the impact of a new pretransplant conditioning regimen on disease-free survival (DFS) in subjects with Ewing sarcoma and the impact of donor-type on treatment-related mortality (TRM) and leukaemia relapse in subjects with acute leukaemia. Direct adjusted survival and cumulative incidence function (CIF) analyses are an important step forward. These analyses can be done using available statistical packages and we encourage readers to use them rather than reporting unadjusted analyses. Finally, we must emphasize direct adjustment can only be done for know prognostic or predictive co-variates, not unknown co-variates. Unknown co-variates will be balanced in randomized trials which is why we do them. So direct adjustment is an important step forward but not a perfect substitute for randomized trials. But any step forward is important. To quote Laozi: (A journey of a thousand miles begins with a single step).

Entities:  

Mesh:

Year:  2019        PMID: 31101889      PMCID: PMC7306148          DOI: 10.1038/s41409-019-0552-y

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  10 in total

1.  Confidence bands for the difference of two survival curves under proportional hazards model.

Authors:  M J Zhang; J P Klein
Journal:  Lifetime Data Anal       Date:  2001-09       Impact factor: 1.588

2.  Causal inference on the difference of the restricted mean lifetime between two groups.

Authors:  P Y Chen; A A Tsiatis
Journal:  Biometrics       Date:  2001-12       Impact factor: 2.571

3.  Pretreatment serum lactate dehydrogenase predicting metastatic spread in Ewing's sarcoma.

Authors:  H D Brereton; R Simon; T C Pomeroy
Journal:  Ann Intern Med       Date:  1975-09       Impact factor: 25.391

4.  SAS macros for estimation of direct adjusted cumulative incidence curves under proportional subdistribution hazards models.

Authors:  Xu Zhang; Mei-Jie Zhang
Journal:  Comput Methods Programs Biomed       Date:  2010-08-17       Impact factor: 5.428

5.  A SAS macro for estimation of direct adjusted survival curves based on a stratified Cox regression model.

Authors:  Xu Zhang; Fausto R Loberiza; John P Klein; Mei-Jie Zhang
Journal:  Comput Methods Programs Biomed       Date:  2007-09-11       Impact factor: 5.428

Review 6.  Adjusting survival curves for confounders: a review and a new method.

Authors:  F J Nieto; J Coresh
Journal:  Am J Epidemiol       Date:  1996-05-15       Impact factor: 4.897

7.  Corrected group prognostic curves and summary statistics.

Authors:  I M Chang; R Gelman; M Pagano
Journal:  J Chronic Dis       Date:  1982

8.  Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings.

Authors:  R Szydlo; J M Goldman; J P Klein; R P Gale; R C Ash; F H Bach; B A Bradley; J T Casper; N Flomenberg; J L Gajewski; E Gluckman; P J Henslee-Downey; J M Hows; N Jacobsen; H J Kolb; B Lowenberg; T Masaoka; P A Rowlings; P M Sondel; D W van Bekkum; J J van Rood; M R Vowels; M J Zhang; M M Horowitz
Journal:  J Clin Oncol       Date:  1997-05       Impact factor: 44.544

9.  Adjusted survival curve estimation using covariates.

Authors:  R W Makuch
Journal:  J Chronic Dis       Date:  1982

10.  Flexible competing risks regression modeling and goodness-of-fit.

Authors:  Thomas H Scheike; Mei-Jie Zhang
Journal:  Lifetime Data Anal       Date:  2008-08-28       Impact factor: 1.588

  10 in total
  3 in total

1.  Adjusted Survival Curves Improve Understanding of Multivariable Cox Model Results.

Authors:  Carly S Lundgreen; Dirk R Larson; Elizabeth J Atkinson; Katrina L Devick; David G Lewallen; Daniel J Berry; Hilal Maradit Kremers; Cynthia S Crowson
Journal:  J Arthroplasty       Date:  2021-06-30       Impact factor: 4.435

2.  Cytomegalovirus gastroenteritis in patients with acute graft-versus-host disease.

Authors:  Yu Akahoshi; Shun-Ichi Kimura; Yuma Tada; Toshihiro Matsukawa; Masaharu Tamaki; Noriko Doki; Naoyuki Uchida; Masatsugu Tanaka; Hirohisa Nakamae; Takuro Kuriyama; Ken-Ichi Matsuoka; Takashi Ikeda; Takafumi Kimura; Takahiro Fukuda; Yoshinobu Kanda; Yoshiko Atsuta; Makoto Murata; Seitaro Terakura; Hideki Nakasone
Journal:  Blood Adv       Date:  2022-01-25

3.  A Retrospective Observational Analysis of Overall Survival with Sipuleucel-T in Medicare Beneficiaries Treated for Advanced Prostate Cancer.

Authors:  Rana R McKay; Jason M Hafron; Christine Ferro; Helen M Wilfehrt; Kate Fitch; Scott C Flanders; Michael D Fabrizio; Michael T Schweizer
Journal:  Adv Ther       Date:  2020-10-07       Impact factor: 3.845

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.